JP2012532851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532851A5 JP2012532851A5 JP2012519021A JP2012519021A JP2012532851A5 JP 2012532851 A5 JP2012532851 A5 JP 2012532851A5 JP 2012519021 A JP2012519021 A JP 2012519021A JP 2012519021 A JP2012519021 A JP 2012519021A JP 2012532851 A5 JP2012532851 A5 JP 2012532851A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- nos
- tlr3
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 31
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 26
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 230000002378 acidificating effect Effects 0.000 claims 7
- 230000007935 neutral effect Effects 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 102000045716 human TLR3 Human genes 0.000 claims 5
- 230000000903 blocking effect Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22454809P | 2009-07-10 | 2009-07-10 | |
| US61/224,548 | 2009-07-10 | ||
| PCT/EP2010/059946 WO2011004028A2 (en) | 2009-07-10 | 2010-07-09 | Tlr3 binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532851A JP2012532851A (ja) | 2012-12-20 |
| JP2012532851A5 true JP2012532851A5 (enExample) | 2013-08-15 |
| JP5800809B2 JP5800809B2 (ja) | 2015-10-28 |
Family
ID=42727505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519021A Expired - Fee Related JP5800809B2 (ja) | 2009-07-10 | 2010-07-09 | Ｔｌｒ３結合剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9388246B2 (enExample) |
| EP (1) | EP2451844B1 (enExample) |
| JP (1) | JP5800809B2 (enExample) |
| CN (1) | CN102471382A (enExample) |
| AU (1) | AU2010270163B2 (enExample) |
| CA (1) | CA2766747C (enExample) |
| DK (1) | DK2451844T3 (enExample) |
| ES (1) | ES2543095T3 (enExample) |
| RU (1) | RU2562865C2 (enExample) |
| WO (1) | WO2011004028A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8460659B2 (en) | 2008-10-31 | 2013-06-11 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
| HUE031756T2 (en) * | 2008-10-31 | 2017-07-28 | Janssen Biotech Inc | TLR3 antagonists |
| WO2010060186A1 (en) | 2008-11-03 | 2010-06-03 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| RU2562865C2 (ru) | 2009-07-10 | 2015-09-10 | Иннэйт Фарма | Tlr3 связывающие агенты |
| US20140065154A1 (en) * | 2011-01-12 | 2014-03-06 | Innate Pharma | Tlr3 binding agents |
| DK3173427T3 (da) | 2011-03-31 | 2019-08-05 | Adc Therapeutics Sa | Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf |
| WO2013078223A1 (en) * | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
| HRP20190946T1 (hr) | 2012-01-09 | 2019-07-26 | Adc Therapeutics Sa | Sredstva za liječenje trostruko negativnog raka dojke |
| EP2870178B1 (en) | 2012-05-09 | 2017-07-12 | Eli Lilly and Company | Anti-c-met antibodies |
| EP2855527B1 (en) * | 2012-05-31 | 2018-08-01 | Innate Pharma | Tlr3 binding agents |
| PT2888593T (pt) * | 2012-08-21 | 2018-12-12 | Janssen Pharmaceutica Nv | Anticorpos contra risperidona e utilizações dos mesmos |
| WO2015084262A2 (en) | 2013-12-03 | 2015-06-11 | Agency For Science, Technology And Research | Cytotoxic antibody |
| EP3186284B1 (en) | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| JP7051715B2 (ja) | 2016-05-13 | 2022-04-11 | バイオアトラ、エルエルシー | 抗Ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用 |
| WO2021146383A1 (en) * | 2020-01-17 | 2021-07-22 | BioLegend, Inc. | Anti-tlr7 agents and compositions and methods for making and using the same |
| US20230348571A1 (en) * | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
| AU2022230408A1 (en) * | 2021-03-03 | 2023-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | La protien as a novel regulator of osteoclastogenesis |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AR006928A1 (es) | 1996-05-01 | 1999-09-29 | Pioneer Hi Bred Int | Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas. |
| EP1798288B1 (en) | 1997-05-07 | 2009-09-16 | Schering Corporation | Human Toll-like receptor proteins, related reagents and methods |
| DK0999853T3 (da) | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| KR20030074693A (ko) | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| WO2003080675A2 (en) | 2002-03-22 | 2003-10-02 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1) |
| JP2004016021A (ja) | 2002-06-12 | 2004-01-22 | Japan Science & Technology Corp | 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット |
| CA2494104A1 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| TWI487535B (zh) * | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途 |
| DK1945820T3 (da) * | 2005-10-27 | 2013-11-11 | Janssen Biotech Inc | Toll-lignende receptor-3-modulatorer, fremgangsmåder og anvendelser |
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| US8354508B2 (en) | 2006-07-21 | 2013-01-15 | Diadexus, Inc. | PRO115 antibody compositions and methods of use |
| EP2081960B1 (en) | 2006-10-27 | 2018-06-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| EP2155249A4 (en) | 2007-05-15 | 2011-11-16 | Oncomed Pharm Inc | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER |
| CA2722589A1 (en) | 2008-04-25 | 2009-10-29 | Innate Pharma | Improved tlr3 agonist compositions |
| US8460659B2 (en) | 2008-10-31 | 2013-06-11 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
| HUE031756T2 (en) | 2008-10-31 | 2017-07-28 | Janssen Biotech Inc | TLR3 antagonists |
| US20130090457A1 (en) | 2008-10-31 | 2013-04-11 | Janssen Biotech, Inc. | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases |
| UA112282C2 (uk) | 2009-04-29 | 2016-08-25 | Янссен Байотек, Інк. | Антагоніст толл-подібного рецептора 3 |
| RU2562865C2 (ru) | 2009-07-10 | 2015-09-10 | Иннэйт Фарма | Tlr3 связывающие агенты |
| EP2332986B1 (en) | 2009-12-11 | 2013-10-09 | Deutsches Krebsforschungszentrum | Antibody that binds to H-1 parvovirus |
| US20140065154A1 (en) | 2011-01-12 | 2014-03-06 | Innate Pharma | Tlr3 binding agents |
| EP2855527B1 (en) | 2012-05-31 | 2018-08-01 | Innate Pharma | Tlr3 binding agents |
-
2010
- 2010-07-09 RU RU2012103212/10A patent/RU2562865C2/ru active
- 2010-07-09 JP JP2012519021A patent/JP5800809B2/ja not_active Expired - Fee Related
- 2010-07-09 EP EP10734092.9A patent/EP2451844B1/en active Active
- 2010-07-09 WO PCT/EP2010/059946 patent/WO2011004028A2/en not_active Ceased
- 2010-07-09 AU AU2010270163A patent/AU2010270163B2/en not_active Ceased
- 2010-07-09 CA CA2766747A patent/CA2766747C/en active Active
- 2010-07-09 CN CN2010800309195A patent/CN102471382A/zh active Pending
- 2010-07-09 ES ES10734092.9T patent/ES2543095T3/es active Active
- 2010-07-09 DK DK10734092.9T patent/DK2451844T3/en active
-
2011
- 2011-05-05 US US13/102,019 patent/US9388246B2/en not_active Expired - Fee Related
-
2016
- 2016-07-07 US US15/204,851 patent/US20160347853A1/en not_active Abandoned